Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05139745 · ClinicalTrials.gov registry record · NA

Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue

A NA study, sponsored by BTL Industries.

Completed
Registry status
NA
Development phase
7
Enrollment target

NCT05139745 is a NA study that has completed, run by BTL Industries. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05139745, a NA study, has completed, sponsored by BTL Industries.

COMPLETED
Registry status
NA
Development phase
7 participants
Enrollment target

Study Summary

This study will evaluate the safety and performance of the BTL-899 device for non-invasive treatment of subcutaneous fat. The changes in the fat tissue related to the activity of caspase-3 will be assessed histologically. The study is a prospective single-center single-blinded two-arm study. The subjects will be enrolled and assigned into two study groups; Group A which will receive active treatment and Group B which receives sham treatment and will serve as a control to verify the treatment outcomes. Subjects will be required to complete only one (1) treatment visit and three (3) follow-up visits (at 8 hours, 24 hours and 7 days post treatment). All of the study subjects will receive the treatment (either active or sham) with the subject device. At the baseline visit, health status will be assessed. Inclusion and exclusion criteria will be verified and informed consent will be signed. Punch biopsies from the treated abdominal area will be taken to examine the changes related to caspase-3 activity.

Interventions

  • DEVICE BTL-899

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2021-10-11
Est. Completion 2022-08-11
Phase NA

Sponsor

BTL Industries

40 total trials

What the Registry Record Tells You About NCT05139745

The ClinicalTrials.gov registry entry for NCT05139745 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BTL Industries, which has 40 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which BTL-899 is the first listed.

NCT05139745 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05139745 about?

NCT05139745 is a clinical study titled "Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue". This study will evaluate the safety and performance of the BTL-899 device for non-invasive treatment of subcutaneous fat. The changes in the fat tissue related to the activity of caspase-3 will be assessed histologically. The study is a prospective single-center single-blinded two-arm study. The sub...

What is the current status of trial NCT05139745?

This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2021-10-11. Estimated completion is 2022-08-11.

What interventions are being tested in trial NCT05139745?

The interventions under investigation include: BTL-899 (DEVICE).

Who is sponsoring clinical trial NCT05139745?

This trial is sponsored by BTL Industries, which has 40 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.